[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592104":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":31,"locations":37,"responsibleParty":54,"collaborators":56,"id":63,"slug":24,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":24,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":24,"enrollmentInfo":71,"targetDuration":24,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":84,"overallStatus":39,"whyStopped":24,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Virginia Commonwealth University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Fearless Immediate Treatment Arm","EXPERIMENTAL","FearLess is a newly developed, empirically-rooted, manualized psychological intervention consisting of an intake + 8 sessions delivered over a 12-week time period. It consists of weekly individual 60- to 90-minute virtual therapy sessions. FearLess will be delivered immediately following enrollment in this arm.",[13],"Behavioral: Fearless in Neuro-Oncology",{"label":15,"type":6,"description":16,"interventionNames":17},"FearLess Delayed Control Arm","FearLess is a newly developed, empirically-rooted, manualized psychological intervention consisting of an intake + 8 sessions delivered over a 12-week time period. It consists of weekly individual 60- to 90-minute virtual therapy sessions. In this arm, the FearLess intervention will begin following a 12-week no-treatment period.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"BEHAVIORAL","Fearless in Neuro-Oncology","FearLess is a newly developed, empirically-rooted, manualized psychological intervention consisting of an intake + 8 sessions delivered over a 12-week time period. It consists of weekly individual 60- to 90-minute virtual therapy sessions.",[15,9],null,[26,29],{"name":27,"affiliation":5,"role":28},"Ashlee R Loughan, Ph.D","PRINCIPAL_INVESTIGATOR",{"name":30,"affiliation":5,"role":28},"Sarah E Braun, Ph.D.",[32],{"name":33,"role":34,"phone":35,"phoneExt":24,"email":36},"Mary Bridgman","CONTACT","804-628-6799","LiveNOW@vcu.edu",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Richmond","Virginia","23298","United States",{"type":45,"coordinates":46},"Point",[47,48],-77.46026,37.55376,{"lat":48,"lon":47},[51],{"name":52,"role":34,"phone":24,"phoneExt":24,"email":53},"Ashlee Loughan, PhD","ashlee.loughan@vcuhealth.org",{"type":55,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[57,60],{"name":58,"class":59},"National Cancer Institute (NCI)","NIH",{"name":61,"class":62},"National Brain Tumor Society","UNKNOWN","100592104",false,"NCT06989086","FearLess in NeuroOncology","FearLess in Neuro-Oncology","Inclusion Criteria:\n\nPatients:\n\n* Self-report a diagnosis of a primary malignant brain tumor (grade II-IV)\n* \\>2 weeks post-cranial resection or biopsy\n* Elevated Fear of Recurrence Distress Rating\n* Primarily English speaking\n* \\>\u002F= 18 years of age at the time of enrollment\n\nCaregivers:\n\n* nonprofessional caregiver to a patient with a primary malignant brain tumor (grade II-IV)\n* Elevated Fear of Recurrence Distress Rating\n* Primarily English speaking\n* \\>\u002F= 18 years of age at the time of enrollment\n\nExclusion Criteria:\n\nPatient \u002F Caregiver Exclusion:\n\n* Cognitive impairment that might prohibit active intervention engagement\n* Inability to understand and provide informed consent\n* Inability to attend virtual sessions due to unstable or no internet connection","ALL","18 Years",{"count":72,"type":73},112,"ESTIMATED","INTERVENTIONAL",[76],"NA","The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist design to finalize the protocol of FearLess in primary malignant brain tumor patients and caregivers",[79,80,81,82,83],"Primary Malignant Brain Tumor","Glioblastoma (GBM)","Astrocytoma","Oligodendroglioma","Caregiver",[85],"brain tumor","2025-09-02",{"date":88,"type":89},"2025-09-09","ACTUAL",{"date":91,"type":89},"2025-06-24",{"date":93,"type":73},"2028-12-31",{"name":5,"class":6},1]